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Background: It has been reported that rs940494 and rs805296 SNPs of apolipoprotein M (apoM) gene may confer
the risk in the development of type 2 diabetes (T2D) and coronary artery disease (CAD) in the Han Chinese.
However, a recent study demonstrated that rs805297 polymorphism is significantly associated with reduced total
high density lipoprotein (HDL) levels in rheumatoid arthritis patients. But the relationship between rs805297 SNP
and CAD has not been explored. The aim of the present study was to elucidate whether the rs805297 mutant allele
is implicated in CAD and links to changes in blood lipid levels in these patients.
Methods: Three hundred CAD patients and three hundred and twelve non-CAD patients were subjected in
the present study. All subjects were confirmed by the angiography. Plasma concentrations of apoM were
semi-quantitatively determined by dot-blotting analysis, and total serum lipid levels were quantified using an
automated RA-1000 (Technician, USA). The genotyping of rs805297 of apoM was analyzed by polymerase chain
reaction–restriction fragment length polymorphism (PCR–RFLP).
Results: Genotype and allele frequencies were not significant (P=0.5798 and 0.3834, respectively) between cases
and controls. Compared with the wild-type C/C genotype, carriers of the C/A and A/A genotypes did not have an
increased risk of CAD, as determined by multiple logistic regression analysis, after adjustment for age, sex, BMI,
history of smoking, hypertension and hypercholesterolemia. (CA, odds ratio = 0.49, 95% confidence interval
0.15–1.87, P = 0.462; AA, odds ratio = 0.51, 95% confidence interval 0.13–1.68, P = 0.534). The plasma concentration
levels of apoM did not differ significantly among carriers of the three genotypes between two groups. Lastly,
control subjects with A/A genotypes had lower total levels of HDL cholesterol than did those with C/C genotypes.
Conclusions: The results presented here suggest that the rs805297 SNP is not associated with an increased risk of
developing CAD, although it does independently correlate with dyslipidaemia in Han Chinese individuals.
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Coronary artery disease (CAD) is one of the most com-
mon causes of death globally, including in China. CAD
is a complex multi-factorial and polygenic disorder that
is thought to result from the interactions of an individu-
al's genetic background and several environmental fac-
tors [1,2].* Correspondence: jiaohaoyang333@163.com
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stated.Apolipoprotein M (apoM) is predominantly present in
HDL, and to a lesser extent in chylomicrons, very low
density lipoprotein (VLDL) and low-density lipoprotein
(LDL) [3]. It plays an important role in reverse choles-
terol transport [4]. The apoM gene is proposed to play a
protective role against the development of CAD [5]. Re-
cent studies suggest that several single nucleotide poly-
morphisms (SNPs), including rs805297, rs940494 and
rs805296 occur in the Han Chinese population.
Rs940494 and rs805296 have been identified to associate. This is an Open Access article distributed under the terms of the Creative
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significantly associated with reduced total HDL levels in
rheumatoid arthritis patients [9]. It is well known that
reduced high-density lipoprotein (HDL) cholesterol
levels is one of risk factors of CAD, but the relationship
between rs805297 and CAD has not been explored.
The objective of the present study was to investigate
whether there is an association between a common SNP
in the apoM gene, namely the C-1065A polymorphism,
and the risk of CAD in a Chinese population. We chose
to evaluate this SNP in particular because it is located in
the apoM promoter region, and changes in apoM ex-
pression levels may increase the risk of CAD or other
complex diseases where lipid levels are pathologically
altered.
Results
The clinical parameters of study subjects in the CAD
and control groups are described in Table 1. There were
no significant differences in gender, age or several con-
ventional risk factors between groups, including habitual
smoking and TC; however, CAD patients demonstrated
significant differences in hypertension, TG, HDL-C and
LDL-C concentrations (Table 1).
The validity of the rs805297 SNP of the apoM gene in
the Han Chinese population was determined by DNA
sequencing (Figure 1). Additionally, the polymorphism
was confirmed by PCR-RFLP (Figure 2).
Genotype distributions and allele frequencies of
rs805297 SNP in CAD cases and controls are summa-
rized in Table 2. Chi square analysis demonstrates the al-
lele frequencies to be in Hardy-Weinberg equilibrium.
There were no significant differences identified between






Age (years) 62.3 ± 10.1 60.8 ± 11.2 0.321
Sex (M/F) 194/106 183/129 0.126
Habitual smoking (%) 42.7 40.1 0.427
BMI (kg/m2) 25.1 ± 3.09 23.9 ± 3.2 0.068
Hypertension
Yes 131* 79 0.000
No 169 233
TC (mmol/L) 4.51 ± 1.31 4.47 ± 1.25 0.072
TG (mmol/L) 2.18 ±0.93* 1.84 ± 1.02 0.013
HDL-C (mmol/L) 1.08 ±0.34* 1.25 ± 0.42 0.032
LDL-C (mmol/L) 2.27 ± 0.97* 2.39 ± 0.78 0.000
Data are presented as mean ± SD for age, body mass index (BMI), total
cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C),
high-density lipoprotein cholesterol (HDL-C), coronary artery disease (CAD).
*p < 0.05 vs control group.(χ2 =1.090, df =2, P = 0.5798) or allele frequencies
(χ2 =0.7597, df =2, P = 0.3834). Compared with the wild-
type C/C genotype, carriers of the C/A and A/A
genotypes did not have an increased risk of CAD, as de-
termined by multiple logistic regression analysis, after
adjustment for age, sex, BMI, history of smoking, hyper-
tension and hypercholesterolemia (Table 3). Our analysis
did not detect any effect of the apoM genotype on the
likelihood of having CAD.
We further analyzed the impact of the rs805297 SNP on
serum lipid concentrations in both CAD patients and con-
trols. Controls carrying the AA polymorphism demon-
strated significantly lower HDL-C concentrations compared
to wild-type CC subjects in control groups (Table 4). It was
reported that rs805297 SNP affects the levels of apoM
mRNA expression in rheumatoid arthritis patients. Lucifer-
ase reporter assay suggested that the C to A substitution at
the promoter region of apoM affects the transcription activ-
ity in vitro [9]. We investigated the plasma concentration of
the apoM protein to determine whether it changes as a
function of the genotypes. The average plasma concentra-
tions of apoM in CAD patients with AA, CA, CC geno-
types were 1.3625 ± 0.1053 ODu.mm-2, 1.3614 ± 0.1271
ODu.mm-2 and 1.3645 ± 0.1432 ODu.mm-2, and in controls
were 1.3630 ± 0.1127 ODu.mm-2, 1.3629 ± 0.1132 ODu.
mm-2 and 1.3643 ± 0.1021 ODu.mm-2, respectively. There
were no significant differences in the plasma concentrations
of apoM between two groups by Wilcoxon signed ranked
test (p > 0.05) (Figure 3).
Discussion
The pathophysiology of atherosclerosis is multifactorial
with environmental, metabolic and genetic components
influencing etiology [10]. A large body of literature has
established a panel of traditional candidate genes impli-
cated in cardiovascular disease, such as angiotensin-
converting enzyme (ACE) and angiotensinogen (AGT).
Variants in these traditional genes are known to be cor-
related with coronary artery disease (CAD). Recent stud-
ies have identified new loci to the growing list of the
candidate genes, including myocyte enhancer factor 2
(MEF2A) and phosphodiesterase 4 (PDE4D) [11]. ApoM
is a novel potential candidate gene that may be protect-
ive against the development of CAD [5].
In present case–control study, we sought to determine
whether rs805297 SNP of the apoM gene alters suscepti-
bility to CAD. First, we compared genotype distributions
and allele frequencies of the apoM gene between CAD
and control groups and then performed a logistic regres-
sion with adjustments for age, sex, BMI, history of
smoking, hypertension and hypercholesterolemia. Our
data identified no relationship between CAD and the
apoM genotype, supporting that rs805297 SNP is not a
risk factor for genetic susceptibility to CAD.
Figure 1 DNA sequencing of the polymorphic region (C-A transition at nucleotide −1065) in the proximal promoter region of the
apoM gene revealed that rs805297(C > A) of apoM gene is valid in Han Chinese. This nucleotide change results in a Tsp509I restriction site.
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rs805297 and rs940494 SNPs of apoM with CAD in
Chinese populations [7,8]. Contrarily, our study did not
detect any differences in genotype distributions and al-
lele frequencies of rs805297 SNP of apoM gene between
CAD and control groups in our Han Chinese subjects.
This may be attributed to different allele frequencies of
apoM rs805297 in our study compared to previous stud-
ies [6], which may be due to differences in age, sex, race,
geographic location or population sample size. Our
study is limited by it’s case–control design; future pro-
spective studies that include haplotype analysis may
overcome some of these limitations [12].
It is thought that apoM plays a role in lipid metabolism;
however, the biological mechanisms of this protein are not
fully understood. Previous studies have identified associa-
tions between apoM and plasma lipoproteins, demonstrat-
ing correlations with size, charge and composition [13].Figure 2 Restriction fragment length polymorphism analysis
results for the apoM rs805297(C > A) locus. Products were
separated on a 4% low molecular weight agarose gel and stained
with ethidium bromide. Lane M, ladder of molecular size markers;
lane 1, CC homozygote; lane 2, CA heterozygote; lane 3,
AA homozygote.Plasma apoM is strongly correlated with total cholesterol
in healthy individuals [14], with apoM concentrations
roughly corresponding to 1/50th of the apoA-I plasma
concentration [15]. This prompted us to investigate the im-
pact of the C-1065A polymorphism on the plasma lipid
profile. Consistent with a recent report [9], our study found
no significant differences between rs805297 SNP and
atherogenic lipids (TC, TG, LDL-C). We found no signifi-
cant differences in HDL between CAD patients with A/A
genotypes and those with C/C or C/A genotypes, although
control subjects with A/A genotypes had lower levels of
HDL than those with C/C or A/A genotypes. It is possible
that statin treatments for hyperlipidemia in CAD patients
modulated the lipid parameters.
The apoM gene is located in histocompatibility com-
plex III (HMC-III) region on chromosome 6. The
rs805297 SNP site is localized to the promoter, which
may affect gene transcription and concomitant protein
levels in the blood to underlie its disease association.
This hypothesis is supported by previous literature indi-
cating that the C allele of rs805296 SNP may increase








CC 154 (51.3%) 147 (47.1%)
CA 137 (45.7%) 155 (49.3%)
AA 9 (3.0%) 10 (3.6%) 0.5798#
C allele 445 (74.2%) 449 (72.0%)
A allele 155 (25.8%) 175 (28.0%) 0.3834##
#Differences of apoM genotypes between CAD patients and controls were
tested in 2 × 3 contingency tables.
##Differences of allele frequencies between CAD patients and controls were
tested in 2 × 2 contingency tables.
CAD, coronary artery disease.
Table 3 Logistic regression analysis for the association
between apoM genotypes and the risk of coronary artery
disease
Genotypes OR 95% CI P-Value
CC 0.41 0.09—1.38 0.452
CA 0.54 0.12—1.63 0.364
AA 0.47 0.16—1.72 0.743
ApoM genotypes were set as categorical variables (homozygote with major
allele = 0; heterozygote = 1; homozygote with minor allele = 2) model. Odds
Ratio (OR) and 95% confidence interval (CI), as well as the P value, were
calculated with adjustment for age, sex, BMI, history of smoking, hypertension
and hypercholesterolemia by logistic regression.
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leagues suggested that rs805297 polymorphism in the
apoM promoter may decrease its transcriptional activity
and thus alter HDL-C concentrations to ultimately affect
RA susceptibility [17]. In light of these previous findings,
we evaluated the impact of rs805297 polymorphism on
plasma concentration of apoM. Based on non-significant
differences in plasma apoM concentrations, our data
suggests that the mutant promoter does not affect apoM
gene expression. It is possible that this polymorphism is
functionally silent which many explain our negative find-
ing. In the present study, we used a semi-quantitative
method to estimate serum apoM levels; therefore, future
studies should apply more precise measures to deter-
mine whether this finding is replicable.
Conclusions
The data in this present study support that the rs805297
SNP is not associated with increased susceptibility to CAD.
Our data indicates that this polymorphism is associated




Subjects recruited for this study consisted of 300 CAD
patients (194 males and 106 females with a mean age of
62.3 ± 10.1 years) and 312 unrelated individuals enrolled as
control subjects (183 males and 129 females with a meanTable 4 Lipid profile values (mmol/L) depending on apoM ge
Genoty
CAD patients (n = 300)
CC CA AA P-Valu
TC 4.52 ± 1.21 4.48 ± 1.45 4.46 ± 1.31 0.694
TG 2.19 ±1.01 2.18 ±1.22 2.21 ±0.97 0.837
HDL-C 1.09 ± 0.23 1.11 ± 0.38 1.05 ± 0.35 0.153
LDL-C 2.25 ± 1.07 2.28 ± 1.13 2.31 ± 0.98 0.147
Data are expressed as mean ± SD. CAD, coronary artery disease; TG, triglycerides; TC
density lipoprotein cholesterol. P value for effect of the ApoM genotypes on plasma
control group.age of 60.8 ± 11.2 years). To be enrolled in the CAD group,
patients, had to have at least 50% stenosis, determined an-
giographically, in at least one of the major segments of cor-
onary arteries, i.e., the right coronary artery, left
circumflex, or left anterior descending arteries. CAD pa-
tients suffering from acute coronary syndrome or undergo-
ing previous cardiovascular events such as angioplasty or
CABG or stenting were not enrolled in CAD group. Con-
trols were required to have a negative coronary artery angi-
ography so as to exclude CAD. History of conventional
risk factors for CAD, including habitual cigarette smoking
(persons with smoking habit smoke more than 1 cigarette
per day averagely), hypertension (systolic blood pressure
≥160 mm Hg and/or diastolic blood pressure ≥95 mmHg),
diabetes mellitus (A diagnosis of diabetes is confirmed if
there are symptoms of diabetes and a plasma glucose level
of at least 11.1 mmol/L, a fasting plasma glucose level of at
least 7 mmol/L; or a two-hour plasma glucose level of at
least 11.1 mmol/L during an oral glucose tolerance test.),
or hypercholesterolemia (TC ≥ 5.7 mmol/L) were obtained
from the subjects or from their medical records. Exclusion
criteria for both the CAD patients and control individuals
included familial hypercholesterolemia, diabetes mellitus,
cancer, renal disease, and any other chronic illnesses. All
subjects in both the CAD and control groups are Han
Chinese from Jiangsu province or Shanghai, China. The re-
search was in agreement with Helsinki declaration. The re-
search was prospectively reviewed and approved by a duly
constituted ethics committee at Nanjing Medical Univer-
sity. Written informed consent was obtained from each
subject before collecting blood samples. A medical history
and a peripheral venous blood specimen were obtained
from all participants; part of this blood sample was ana-
lyzed for plasma levels of fasting glucose, triglycerides
(TG), total cholesterol (TC), HDL–cholesterol (HDL-C)
and LDL–cholesterol (LDL-C), all of which were measured
using an automated RA-1000 (Technician, USA).
Genotyping of the human apoM gene
Five milliliters (5 ml) of venous blood was collected from
each subject into 50 mmol/L disodium EDTA as annotypes
pe
Control subjects (n = 312)
e CC CA AA P-Value
4.48 ± 1.27 4.45 ± 1.19 4.43 ± 1.06 0.482
1.93 ± 1.12 1.81 ± 1.05 1.88 ± 0.97 0.631
1.27 ± 0.42 1.24 ± 0.37 1.07 ± 0.39* 0.043
2.39 ± 0.75 2.38 ± 0.83 2.33 ± 0.68 0.298
, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-













Figure 3 Plasma concentrations of apoM among different genotypes of rs805297 of apoM for both CAD patients and controls. The
average plasma concentrations of apoM in CAD patients of AA, CA, CC genotypes were 1.3625 ± 0.1053 ODu.mm-2, 1.3614 ± 0.1271 ODu.mm-2
and1.3645 ± 0.1432 ODu.mm-2, and in controls were 1.3630 ± 0.1127 ODu.mm-2, 1.3629 ± 0.1132 ODu.mm-2 and1.3643 ± 0.1021 ODu.mm-2,
respectively. There were no significant differences in the plasma concentrations of apoM among these three genotypes in these subjects by
Wilcoxon signed ranked test (p ≥ 0.05).
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ipheral blood leukocytes, as described previously [18].
The apoM polymorphism was analyzed by polymerase
chain reaction–restriction fragment length polymorphism
(PCR–RFLP). DNA was amplified using the following
primers: forward primer, 5′-GCTTTGCAAACATTAC
TATTCAT-3′, reverse primer, 5′-ATTGGCAAATCAT
CAATCTTATA-3′.6 Amplification reactions were per-
formed in a total volume of 50 μl containing: 1 μg of gen-
omic DNA, 12.5 pmol of each primer, 2.5 mmol/L each of
dCTP, dTTP, dGTP, and dATP, 2 U of Taq DNA polymer-
ase (Promega, USA), 50 mmol/L KCl, 1.5 mmol/L MgCl2.
0.1% Triton X-100 and 10 mmol/L Tris–HCl (pH 9.0 at
25°C). The thermocycling procedure consisted of an initial
denaturation at 94°C for 5 min; 35 cycles of denaturation
(94°C for 30 s), annealing (48°C for 30 s), and extension
(72°C for 30 s); and a final extension at 72°C for 5 min.
PCR products were first subject to restriction digest by
Tsp509I for 16 h at 65°C; the reaction was performed in a
total volume of 20 μl containing 1 μg of PCR product;
5 U of restriction endonuclease Tsp509I (New England
Biolabs, USA) and 2 μl of restriction enzyme buffer. Geno-
types were then used to detect the presence of apoM poly-
morphisms on a 4% low molecular weight agarose gel
electrophoresis system (Promega, USA) and visualized by
ethidium bromide staining. The Cys→Ala substitution cre-
ates a Tsp509I restriction site in the rs805297 polymorph-
ism of apoM. PCR products with an Ala allele were
digested into two fragments (79 and 44 bp), whereas the
PCR product with the Cys allele could not be cut by
Tsp509I. To confirm detection of the C-1065A polymorph-
ism of the apoM gene by PCR–RFLP, PCR products were
purified with Centricon-100 filtration devices (Amicon,
Beverly, MA, USA) and sequenced directly with afluorescence-based automated DNA sequencer (Applied
Biosystems, Foster City, CA, USA). All experiments were
performed in duplicate in order to obtain precise assess-
ments of genotype for each subject.
Measurement of plasma apoM concentration
Plasma apoM concentration was estimated by dot-blot
analysis using monoclonal rabbit anti-human apoM anti-
body (ABNOVA). Briefly, 10 μl of plasma was diluted
1:20 in Tris–HCl buffer and 5 μl of the diluted samples
was applied to a membrane in triplicate (Hybond-C,
Amersham Life Science). Membranes were quenched in
Tris–HCl buffer with 4% Tween and 3% bovine serum
albumin for 2 hours, followed by sequential incubations
with monoclonal rabbit anti-human apoM antibody
(1:1000 in Tris–HCl buffer) overnight at 4°C, and then
alkaline phosphatase (AP)-conjugated secondary anti-
body for 2 hours at room temperature. AP levels were
measured with a commercial visualization system follow-
ing the manufacturer’s instructions (Dako). The recom-
binant ApoM protein (ABNOVA) and ddH2O were used
as positive and negative controls for evaluation, respect-
ively. The relative amounts of apoM in diluted plasma
samples were quantified by a scanner using the Quantity
One software (Version 4.2.1, Bio- Rad Laboratories) and
presented as adjusted volume (ODu.mm-2). Each experi-
ment was repeated at least in triplicate.
Statistical analysis
Clinical data from CAD patients and control subjects
was compared by the unpaired Student's t test or the
Mann–Whitney U test. Allele frequencies were estimated
by the gene-counting method, and the χ2 test was used to
identify significant variations from the Hardy–Weinberg
Cao et al. Lipids in Health and Disease 2013, 12:184 Page 6 of 6
http://www.lipidworld.com/content/12/1/184equilibrium. We employed two models to assess differences
in allele frequencies and genotypes between CAD patients
and controls: comparing allele frequencies in 2 × 2 contin-
gency tables or genotypes in 2 × 3 contingency tables. We
also performed multivariable logistic regression analysis to
adjust for risk factors. CAD was assigned as a dependent
variable, and the independent variables included age, body
mass index, gender (male = 0, female = 1), smoking status
(0 = nonsmoker, 1 = smoker), metabolic variables (0 = no his-
tory of hypertension, or no hypercholesterolemia; 1 = posi-
tive history), and apoM genotype. All genotypes were set as
categorical variables (homozygote with major allele = 0; het-
erozygote = 1; homozygote with minor allele = 2). The OR
and 95% CI were also calculated. Plasma apoM levels for the
different genotypes were compared between two groups by
Wilcoxon signed ranked test, and the significance threshold
was set to P= 0.05. Statistical analysis was done using the
SPSS statistical software package version 11.5.
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